Clinical trials: sponsored by Akeso
Hepatocellular Carcinoma
A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection
The efficacy and safety of AK104 as adjuvant therapy in hepatocellular carcinoma of high recurrence risk after curative resection.
- Trial name
- NCT05489289
- Testing
- AK104
- Where
- China
- Volunteers
- 570 people
- Sponsor
- Akeso
NSCLC (Non-small Cell Lung Cancer)
A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC
This study compares the efficacy and safety of AK104 versus Sugemalimab as consolidation therapy in patients with unresectable, locally advanced NSCLC who have not progressed following concurrent or sequential chemoradiotherapy.
- Trial name
- NCT06617416
- Testing
- Cadonilimab (AK104), Sugemalimab
- Where
- China
- Volunteers
- 560 people
- Sponsor
- Akeso
Recurrent Ovarian Cancer
An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer
An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer
- Trial name
- NCT06560112
- Testing
- AK104, AK112, Chemotherapy
- Where
- China
- Volunteers
- 172 people
- Sponsor
- Akeso
Solid Tumor, Adult
A Study of AK112 for Advanced Solid Tumors
This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of AK112, a PD-1/VEGF bispecific antibody, as a single agent in adult subjects with…
- Trial name
- NCT04597541
- Testing
- AK112
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Akeso
Nasopharyngeal Carcinoma
A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma
This is a multi-center, randomized, open-label, phase II study to evaluate the efficacy and safety of anti-PD-1 antibody Penpulimab (AK105) combined with chemotherapy ± anlotinib hydrochloride in the first-line treatment of…
- Trial name
- NCT04736810
- Testing
- AK105, Cisplatin, Gemcitabine
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Akeso
Solid Cancer
A Phase I Study of AK138D1 in the Treatment of Advanced Solid Tumors
This is an open-label, first-in-human, Phase I clinical study aimed at evaluating the safety, tolerability, PK, immunogenicity, and preliminary antitumor efficacy of AK138D1 in subjects being treated for advanced solid tumors.
- Trial name
- NCT06730386
- Testing
- AK138D1
- Where
- 4 sites in Australia
- Volunteers
- 100 people
- Sponsor
- Akeso
Hyperlipidemia
A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With Hyperlipidemia
This is a randomized, double-blind, placebo-controlled phase # clinical study evaluating the efficacy and safety of AK102 Q6W in patients with primary hypercholesterolemia and mixed hyperlipidemia.
- Trial name
- NCT05260411
- Testing
- AK102
- Where
- 2 sites in China
- Volunteers
- 246 people
- Sponsor
- Akeso
Chemotherapy-induced Peripheral Neuropathy (CIPN)
AK135 in Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN)
A Phase I open label, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of AK135 for the treatment of chemotherapy-induced peripheral neuropathy in patients with…
- Trial name
- NCT06860789
- Testing
- AK135
- Where
- 2 sites in China
- Volunteers
- 85 people
- Sponsor
- Akeso
Hyperlipidemia
A Study to Evaluate the Efficacy and Safety of AK102 in Patients With Hyperlipidemia
This is a randomized, double-blind, placebo-controlled phase 3 clinical study evaluating the efficacy and safety of AK102 in patients with primary hypercholesterolemia and mixed hyperlipidemia.
- Trial name
- NCT05255094
- Testing
- AK102
- Where
- China
- Volunteers
- 464 people
- Sponsor
- Akeso
Psoriasis
A Study of AK111 in Subjects With Moderate-to-severe Plaque Psoriasis
This is a Phase Ib clinical study of multiple dose escalation of AK111 in subjects with moderate-to-severe plaque psoriasis
- Trial name
- NCT05504317
- Testing
- AK111
- Where
- 2 sites in China
- Volunteers
- 48 people
- Sponsor
- Akeso
Atopic Dermatitis
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AK120 in Subjects With Atopic Dermatitis
This is a randomized, double-blind, placebo-controlled, multicenter phase Ib/II clinical study to evaluate the safety, pharmacokinetics and efficacy of AK120 in the treatment of subjects with moderate to severe atopic dermatitis.
- Trial name
- NCT06035354
- Testing
- AK120
- Where
- 39 sites in China
- Volunteers
- 427 people
- Sponsor
- Akeso
Recurrent or Metastatic Cervical Cancer
A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer
This is a multicenter, open-label, phase II clinical study conducted in China. All subjects will receive AK104 in combination with standard treatment regimens or AK104 alone. The primary end point is safety.
- Trial name
- NCT04868708
- Testing
- AK104, Bevacizumab, Paclitaxel
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Akeso
Acute Myeloid Leukemia
A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia
This is a open label, phase Ib/II study. All patients are diagnosed with AML, Eastern Cooperative Oncology Group (ECOG) performance status 0-3.
- Trial name
- NCT04980885
- Testing
- AK117, Azacitidine
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Akeso
Neoplasms Malignant
A Phase 1 Dose Escalation and Expansion Study of AK117
This is a multicenter, open label, single arm, Phase 1，dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacodynamics, PK, immunogenicity, and preliminary antitumor activity of AK117…
- Trial name
- NCT04728334
- Testing
- AK117
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Akeso
Plaque Psoriasis
A Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and the preliminary efficacy of AK101，an anti-IL-12/23p40 monoclonal antibody, when administered…
- Trial name
- NCT04172233
- Testing
- AK101
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Akeso
Myelodysplastic Syndrome
A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome
This is a open label, phase I/II study. All patients are diagnosed with higher-risk MDS, Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- Trial name
- NCT04900350
- Testing
- AK117, Azacitidine
- Where
- China
- Volunteers
- 136 people
- Sponsor
- Akeso
Healthy Volunteers
A Clinical Study of AK115 in Healthy Subjects
This trial is a randomized, double-blind, placebo-controlled dose escalation phase I trial following single dose subcutaneous administration of AK115 injection.
- Trial name
- NCT05286970
- Testing
- AK115
- Where
- China
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Akeso
Gynecologic Cancer, Cancer Metastatic
Study of AK112 in the Treatment of Advanced Gynecological Tumors
A phase II study to evaluate the efficacy and safety of AK112 in subjects with advanced gynecological tumors.
- Conditions
- Gynecologic Cancer, Cancer Metastatic, Ovarian Neoplasms, Cervical Neoplasm
- Trial name
- NCT04870177
- Testing
- AK112
- Where
- 2 sites in China
- Volunteers
- 53 people
- Sponsor
- Akeso
Advanced or Metastatic Solid Tumors
A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors
This is a first-in-human (FIH), Phase 1a/1b, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of AK119 (Anti-CD73) in Combination with AK104 in…
- Trial name
- NCT04572152
- Testing
- AK119, AK104
- Where
- 5 sites in Australia
- Volunteers
- 23 people
- Sponsor
- Akeso
Hypercholesterolaemia
A Study of PCSK9 Inhibitor AK102 in Healthy Subjects
This is a first-in-human,randomized, double-blind, placebo-controlled, single dose escalation, phase 1 study to evaluate the safety, tolerability, PK/PD and immunogenicity of AK102 administered subcutaneously in healthy subjects.
- Trial name
- NCT04169386
- Testing
- AK102
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Akeso